HeartBeam, Inc. — Form 8-K Summary
Reporting period and context: The filing reports corporate governance and management changes. The earliest reported event occurred June 5, 2023; the report was signed and includes a press release dated June 8, 2023. HeartBeam is a Delaware corporation whose common stock and warrants trade on Nasdaq under BEAT and BEATW, respectively.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial performance figures.
Material Changes
- The Board appointed Mark Strome and Ken Nelson as directors effective June 5, 2023.
- To accommodate the appointments, the Board increased its authorized size from five to seven directors.
- Mr. Strome was appointed to the Compensation Committee. Mr. Nelson was not serving on a Board committee as of the filing.
- Chief Financial Officer Richard Brounstein announced plans to retire, with his resignation effective October 31, 2023.
- Mr. Brounstein agreed to provide CFO advisory services as needed to support the transition.
Management Commentary, Risks, and Unusual Items
- Mr. Strome brings more than 40 years of investment management and securities-industry experience, including experience with private placements, venture capital, private equity, and public-company boards.
- Mr. Nelson brings approximately 20 years of experience in digital health, medical devices, wearables, and cardiac remote patient monitoring, including commercial leadership roles at BioTelemetry, iRhythm, Bardy Diagnostics, and Biotronik.
- The filing states that neither appointee has a family relationship with current officers or directors and that no reportable related-party transactions exist under Item 404(a) of Regulation S-K.
- The CFO transition may create execution or reporting-continuity risk, although the company expects advisory support from Mr. Brounstein to facilitate a smooth transition.
Important Facts for Investors to Verify
- Confirm the effective date and completion of Mr. Brounstein’s CFO retirement and any successor appointment.
- Review the filed June 8, 2023 press release for additional information regarding the director appointments.
- Assess the backgrounds, independence, committee assignments, and compensation arrangements of Messrs. Strome and Nelson in subsequent filings.
- Review subsequent periodic reports for any effects of the Board expansion or CFO transition on financial reporting, liquidity, or corporate strategy.